validation cohorts. Model performance of the final bootstrapped model was assessed in the training and validation cohorts using receiver operating characteristic (ROC) curves with area under the curve (AUC) statistics; ROC curves compare sensitivity to
Search Results
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study
Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett, and Daniel G. Stover
Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy
Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl
distribution of stage, year of diagnosis, and risk category in the treatment groups. Table 1. Patient Characteristics Some deviation from protocol-defined treatment was noted in the treatment groups ( supplemental eTable 1 ). In the chemo-PRT group, 3D
Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma
Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh
noncardia primaries. Demographic and clinical characteristics stratified by type of preoperative treatment are summarized in Table 1 . Among patients treated with preoperative chemotherapy, 43.8% of patients received adjuvant therapy (among whom 67
Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review
Jenna F. Borkenhagen, Daniel Eastwood, Deepak Kilari, William A. See, Jonathan D. Van Wickle, Colleen A. Lawton, and William A. Hall
subclassification ( P <.001). This was a generally healthy cohort, with a CDCI score of 0 in 88% of men, indicating no comorbid conditions recorded ( P =.415). Table 2. Baseline Patient Characteristics Baseline tumor characteristics across cT2 subclassifications
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma
Ang Li, Qian Wu, Suhong Luo, Greg S. Warnick, Neil A. Zakai, Edward N. Libby, Brian F. Gage, David A. Garcia, Gary H. Lyman, and Kristen M. Sanfilippo
of the Declaration of Helsinki. Use of the VHA database was approved by the St. Louis Veterans Affairs Medical Center IRB. Results Cohort Descriptions Baseline patient characteristics for the derivation (SEER-Medicare) and external validation (VHA
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study
Yan Hiu Athena Lee, Jiandong Zhou, Jeremy Man Ho Hui, Xuejin Liu, Teddy Tai Loy Lee, Kyle Hui, Jeffrey Shi Kai Chan, Abraham Ka Chung Wai, Wing Tak Wong, Tong Liu, Kenrick Ng, Sharen Lee, Edward Christopher Dee, Qingpeng Zhang, and Gary Tse
users. HbA1c (expressed as a percentage) was similar in both metformin and sulfonylurea users (mean [SD], 7.45 [1.47] vs 7.45 [1.42], respectively; SMD, <0.01). Baseline and clinical characteristics of the study cohort before and after propensity score
Primary Palliative Care Improves Uptake of Advance Care Planning Among Patients With Advanced Cancers
Michael G. Cohen, Andrew D. Althouse, Robert M. Arnold, Douglas White, Edward Chu, Margaret Rosenzweig, Kenneth J. Smith, and Yael Schenker
intervention increased ACP uptake. Baseline characteristics of patients in the CONNECT intervention and standard care arms are presented using frequency and percentages for categorical variables and mean [SD] for continuous variables. Baseline characteristics
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park
Clinical Characteristics (N=406) At baseline assessment, most patients (79.3%; n=322/406) did not have neuropathy symptoms (CTCAE grade 0; Table 1 ). By midtreatment (8.9 ± 4.8 weeks from baseline), 62.2% (n=199/320) had CIPN symptoms (CTCAE grade ≥1
Changes in Prognostic Beliefs of Patients With Metastatic Cancer and Their Association With Changing Health Status
Isabella Gupta, Eric Andrew Finkelstein, Semra Ozdemir, and Chetna Malhotra
constituted a change in belief from the previous time point. Table 1. Sample Characteristics at Baseline Figure 1. Prognostic beliefs at each time point. Figure 2. Changes in prognostic belief from previous time point. Consistent with
Anal Carcinoma Therapy: Can We Improve on 5-Fluorouracil/Mitomycin/Radiotherapy?
Yixing Jiang, Heath Mackley, Hua Cheng, and Jaffer A. Ajani
Characteristics Among the Major Phase III Studies Ajani et al. 31 showed that patients with tumors greater than 5 cm, irregardless of nodal status, had a higher colostomy rate and inferior disease-free survival. Roohipour et al. 32 showed that treatment
